Observational analysis identifies key microRNAs as prognostic biomarkers in CML patients, suggesting their potential utility in treatment response assessment.
Key Points
MicroRNAs show promise as prognostic markers in chronic myeloid leukemia (CML) patients, particularly in progression and therapy response.
In a cohort of 52 CML patients, 97 microRNAs differed significantly between TKI naive and blast crisis patients, indicating their diagnostic potential.
The study utilized NanoString platform and LIMMA analysis to evaluate microRNA expression in blood samples collected from new CML patients before and during treatment.
These findings may enable the validation of microRNAs as biomarkers in CML, highlighting the need for further studies to confirm their role in clinical practice.